Loading…
Aytu BioPharma, Inc. is projected to rise to $2.39 by 2027, a +6% move from its current price of $2.25. AYTU is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $2.20 | $2.25 | $2.30 | +0.04% |
| Jul 14 | $2.18 | $2.25 | $2.32 | +0.08% |
| Jul 15 | $2.17 | $2.25 | $2.34 | +0.11% |
| Jul 16 | $2.15 | $2.25 | $2.36 | +0.15% |
| Jul 17 | $2.14 | $2.25 | $2.37 | +0.19% |
| Jul 18 | $2.13 | $2.26 | $2.38 | +0.23% |
| Jul 19 | $2.13 | $2.26 | $2.39 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.13 | $2.26 | $2.39 | +0.27% |
| Week 2 | $2.08 | $2.26 | $2.46 | +0.53% |
| Week 3 | $2.05 | $2.27 | $2.51 | +0.80% |
| Week 4 | $2.02 | $2.27 | $2.56 | +1.06% |
| Week 5 | $2.00 | $2.28 | $2.60 | +1.33% |
| Week 6 | $1.98 | $2.29 | $2.64 | +1.60% |
| Week 7 | $1.96 | $2.29 | $2.68 | +1.87% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of ADHD, including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD.
The company also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency.
The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma is headquartered in Denver, Colorado.
AYTU is the stock ticker for Aytu BioPharma, Inc., a healthcare company with a focus on ADHD prescription therapies. It currently trades at $2.25 per share and carries a market capitalization of $24.15M, ranking 4553 in market size.
Near term, the trajectory is described as NEUTRAL, with a 2026 forecast averaging $2.25 per share (range $2.08 to $3.05). The longer-term outlook envisions a bullish path, with the average price rising to $2.97 by 2030 and to $13.26 by 2050, with notable increases in earlier milestones such as 2040 averaging $5.90. This indicates meaningful upside potential over the longer horizon, albeit with variability each year.
A major floor 11.9% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
Price is pressing into resistance (2.7% away) — a breakout level to watch.
A major ceiling 21.3% above — clearing it would confirm fresh momentum.
Key AYTU support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AYTU market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $2.21 | Buy | $2.21 | Buy |
| MA 10 | $2.19 | Buy | $2.20 | Buy |
| MA 20 | $2.19 | Buy | $2.20 | Buy |
| MA 50 | $2.25 | Sell | $2.26 | Sell |
| MA 100 | $2.40 | Sell | $2.33 | Sell |
| MA 200 | $2.37 | Sell | $2.32 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.26 | Neutral |
| Stoch RSI (14) | 99.77 | Sell |
| CCI (20) | 105.26 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 0.00 | Neutral |
| Bollinger %B (20,2) | 0.79 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.13 | Sell |
| Awesome (5,34) | 0.02 | Buy |
| Ultimate (7,14,28) | 59.75 | Neutral |
| Momentum (10) | 0.08 | Buy |
| Aroon Osc (25) | 8.00 | Buy |
| Hull MA (9) | 2.23 | Buy |
| ADX (14) | 9.96 | Neutral |
| ATR (14) | 0.04 | Info |
The near-term technical picture shows NEUTRAL sentiment, with RSI14 at 50. The moving averages are aligned around the current price, with SMA50 at $2.35 and SMA200 at $2.37.
Support is positioned at $2.08 and resistance at $2.50, creating a defined trading range around the current level.
Over the last 30 days, the price range has spanned from $1.86 to $2.73, signaling modest volatility within a tight band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.08 | $2.25 | $2.90 | 0% | Neutral | |
| $1.94 | $2.39 | $3.11 | +6% | Neutral | |
| $1.99 | $2.52 | $3.37 | +12% | Neutral | |
| $1.98 | $2.55 | $3.51 | +14% | Neutral | |
| $2.20 | $2.88 | $4.04 | +28% | Bullish | |
| $2.50 | $3.32 | $4.74 | +48% | Bullish | |
| $2.62 | $3.53 | $5.12 | +57% | Bullish | |
| $2.84 | $3.87 | $5.71 | +72% | Bullish | |
| $2.72 | $3.75 | $5.61 | +67% | Bullish | |
| $2.66 | $3.71 | $5.61 | +65% | Bullish | |
| $3.66 | $5.38 | $8.59 | +139% | Bullish | |
| $6.96 | $11.19 | $19.32 | +397% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.08 | $2.25 | $2.65 | +0.00% |
| August 2026 | $1.91 | $2.25 | $2.70 | -0.14% |
| September 2026 | $1.97 | $2.33 | $2.83 | +3.66% |
| October 2026 | $1.99 | $2.36 | $2.89 | +1.53% |
| November 2026 | $1.95 | $2.33 | $2.87 | -1.58% |
| December 2026 | $1.96 | $2.34 | $2.90 | +0.70% |
Click any year to see its month-by-month AYTU forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
In 2026, AYTU is projected to trade between $2.08 and $2.90, averaging $2.25 — a potential gain of 0% from today's $2.25. Price action looks broadly range-bound.
Aytu BioPharma, Inc.'s 2027 outlook centres on $2.39, within a $1.94 to $3.11 range. That is up +6% on the projected 2026 average. That marks a +6% change versus current levels. A consolidation phase looks the most probable path here.
By 2028, AYTU could reach as high as $3.37, with a base case around $2.52 and support toward $1.99 — roughly +12% from $2.25. Price action looks broadly range-bound.
Expect AYTU to range from $1.98 to $3.51 through 2029. The $2.55 average target implies a +14% move from current prices. That is up +2% on the projected 2028 average. A consolidation phase looks the most probable path here.
The AYTU price prediction for 2030 points to an average of $2.88 (low $2.20, high $4.04) — a potential gain of +28% on today's $2.25. Momentum favours further upside here.
In 2031, AYTU is projected to trade between $2.50 and $4.74, averaging $3.32 — a potential gain of +48% from today's $2.25. That is up +15% on the projected 2030 average. Buyers look set to stay in control over this stretch.
Aytu BioPharma, Inc.'s 2032 outlook centres on $3.53, within a $2.62 to $5.12 range. That is up +6% on the projected 2031 average. That marks a +57% change versus current levels. Momentum favours further upside here.
By 2033, AYTU could reach as high as $5.71, with a base case around $3.87 and support toward $2.84 — roughly +72% from $2.25. Buyers look set to stay in control over this stretch.
Expect AYTU to range from $2.72 to $5.61 through 2034. The $3.75 average target implies a +67% move from current prices. That is -3% versus the projected 2033 average. Momentum favours further upside here.
The AYTU price prediction for 2035 points to an average of $3.71 (low $2.66, high $5.61) — a potential gain of +65% on today's $2.25. Buyers look set to stay in control over this stretch.
In 2040, AYTU is projected to trade between $3.66 and $8.59, averaging $5.38 — a potential gain of +139% from today's $2.25. That is up +45% on the projected 2035 average. Momentum favours further upside here.
Aytu BioPharma, Inc.'s 2050 outlook centres on $11.19, within a $6.96 to $19.32 range. That is up +108% on the projected 2040 average. That marks a +397% change versus current levels. Buyers look set to stay in control over this stretch.
Investing $1,000 in AYTU today (≈ 444.444444 AYTU) could be worth
$4,972.04
+$3,972.04 (+397%) by 2050 · US Dollar
Based on the average projected AYTU price of $11.19 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AYTUwould be worth at today's price.
$1,000 invested in AYTU on Jul 10, 2025 (≈ 436.68123 AYTU) would be worth
$982.53
-$17.47 (-1.7%) today · 0.98× · US Dollar
Based on a AYTU entry price of $2.29 vs. today's $2.25.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $2.16 | $1,041.67 | +4.2% |
| 1 month ago | $2.24 | $1,004.46 | +0.4% |
| 3 months ago | $2.55 | $882.35 | -11.8% |
| 6 months ago | $2.68 | $839.55 | -16.0% |
| 1 year ago | $2.29 | $982.53 | -1.7% |
| All time (5.0y) ago | $91 | $24.73 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AYTU forecast.
Our base-case forecast reaches $4.50 around 2040.
Implied market cap at $4.50: $48.3M
The multi-year forecast turns bullish after the near term, with a clear uplift in expected prices beginning around 2030. In 2030, the average price is projected at $2.97 with a 32.2 ROI and a maximum around $4.39. The 2031–2033 period continues the ascent, with 2031 at an average of $3.60 and a Bullish sentiment, followed by higher averages in 2032 ($3.91) and 2033 ($4.15) and continued gains through 2035.
By 2040, the average is forecast at $5.90 with a 162.2 ROI, and by 2050 the average rises to $13.26 with a 489.3 ROI, reflecting substantial long-run upside. These estimates illustrate a progression from neutral near-term to strong bullish momentum over the coming decades.
These figures are estimates, not guarantees. Actual results will depend on market conditions and company performance, and there is inherent uncertainty in long-range projections.
Tap a question to reveal the answer.
In 2030 the forecast shows min $2.18, avg $2.97, max $4.39 with ROI 32.2 and a BULLISH sentiment.
The 2031 forecast lists min $2.58, avg $3.60, max $5.43 with ROI 59.9 and a BULLISH sentiment, indicating a potential move above $5 in that year.
For 2026 the average price is $2.25 with a min of $2.08 and a max of $3.05, and the sentiment is NEUTRAL.
In 2040 the average is $5.90 with ROI 162.2; in 2050 the average is $13.26 with ROI 489.3, both labeled BULLISH.
The forecast shows meaningful upside later in the horizon, with bullish sentiment in 2030 and beyond and substantial potential by 2050 (average $13.26, ROI 489.3). Near term remains NEUTRAL, and these are estimates, not guarantees.
Aytu BioPharma, Inc. Community Discussion
0Share your Aytu BioPharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.